O3‐06‐07: GSI‐953 is a potent APP‐selective gamma‐secretase inhibitor for the treatment of Alzheimer's disease
Steven J. Jacobsen(Mayo Clinic), Robert Martone(Princeton University), S. Bradley Forlow, Scott C. Mayer, Menelas N. Pangalos(AstraZeneca (United Kingdom)), Cathleen Gonzales, David Riddell(Eli Lilly (United States)), Jonathan Bard, Peter H. Reinhart(University of Massachusetts Amherst), Carrie Balliet, Michael E. Burczynski(Teva Pharmaceuticals (United States)), Anthony F. Kreft, Hong Wan, Boyd L. Harrison, Margaret M. Zaleska, Glen Frick, Thomas A. Comery(Princeton University)
Cited by 12
Related Papers
ApoE Promotes the Proteolytic Degradation of Aβ
|Neuron|2008|869
Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities
|Nature Reviews Neurology|2020|504
Application of the Bicyclo[1.1.1]pentane Motif as a Nonclassical Phenyl Ring Bioisostere in the Design of a Potent and Orally Active γ-Secretase Inhibitor
|Journal of Medicinal Chemistry|2012|460
Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels
|Journal of Neuroscience|2008|351
Compartmentalization of β-secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts
|Current Biology|2001|302